Page last updated: 2024-10-29

indomethacin and Pancreatic Diseases

indomethacin has been researched along with Pancreatic Diseases in 2 studies

Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.

Pancreatic Diseases: Pathological processes of the PANCREAS.

Research Excerpts

ExcerptRelevanceReference
"Pancreatitis is the most common complication of pancreatic extracorporeal shock wave lithotripsy (ESWL)."3.11Rectal indometacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): a single-centre, double-blind, randomised, placebo-controlled trial. ( Chen, H; Du, YQ; Guo, JY; Hu, LH; Jin, ZD; Li, B; Li, ZS; Liao, Z; Pan, J; Qian, YY; Ru, N; Tang, XY; Wang, D; Wang, LW; Wu, H; Xin, L; Zou, WB, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Qian, YY1
Ru, N1
Chen, H1
Zou, WB1
Wu, H1
Pan, J1
Li, B1
Xin, L1
Guo, JY1
Tang, XY1
Hu, LH1
Jin, ZD1
Wang, D1
Du, YQ1
Wang, LW1
Li, ZS1
Liao, Z1
Adler, DG1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)[NCT02797067]Phase 41,370 participants (Actual)Interventional2016-05-31Completed
Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis: A Multicenter, Prospective, Randomized Clinical Trial[NCT05772234]1,066 participants (Anticipated)Interventional2023-11-17Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

the Incidence of Post-ESWL Pancreatitis

Patients were identified as post-ESWL pancreatitis if meeting two out of three criteria: pain consistent with acute pancreatitis; amylase or lipase>3 times normal limit; characteristic findings on imaging, in according to the Revised Atlanta International consensus. (NCT02797067)
Timeframe: up to 1 months

InterventionParticipants (Count of Participants)
Indomethacin60
Glycerin84

the Incidence and Severity of Asymptomatic Hyperamylasemia and Other Post-ESWL Complications

"Asymptomatic hyperamylasemia was defined as an increase in serum amylase compared with pre-ESWL levels and beyond the upper limit of the normal range but showing no related symptoms. Serum amylase will be measured in all study patients at 3 and 24 hours after the procedure and subsequently at clinical discretion.~Other post-ESWL complications including bleeding, infection, steinstrasse and perforation.~Bleeding is related to clinical evidence,the level of hemoglobin ( measured at 24 hours after the procedure and at clinical discretion) and treatments.~Infection is related to temperature and treatment. Steinstrasse is related to abdominal pain degree and the combination of other complications.~Perforation is related to treatment." (NCT02797067)
Timeframe: up to 1 months

,
InterventionParticipants (Count of Participants)
InfectionSteinstrassePerforationAsymptomatic HyperamylasemiaHematuriaHematemesisMelena
Glycerin1311197251416
Indomethacin50018918919

the Severity of Post-ESWL Pancreatitis Measured as Consensus Definitions for the Major Complications of ERCP(Endoscopic Retrograde Cholangiopancreatography )

Post-ESWL complications are also stratified as mild, moderate and severe depending mainly on the length of hospitalization and the need for invasive treatment. (NCT02797067)
Timeframe: up to 1 months

,
InterventionParticipants (Count of Participants)
MildModerateSevere
Glycerin7950
Indomethacin5910

Reviews

1 review available for indomethacin and Pancreatic Diseases

ArticleYear
Best of pancreaticobiliary endoscopy: 2015-2016.
    Gastrointestinal endoscopy, 2017, Volume: 85, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Biliary Tract Diseases; Biopsy, Large-Core Needle; Cholangi

2017

Trials

1 trial available for indomethacin and Pancreatic Diseases

ArticleYear
Rectal indometacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): a single-centre, double-blind, randomised, placebo-controlled trial.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Calculi; Double-Blind Method; Female; Humans; Indome

2022
Rectal indometacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): a single-centre, double-blind, randomised, placebo-controlled trial.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Calculi; Double-Blind Method; Female; Humans; Indome

2022
Rectal indometacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): a single-centre, double-blind, randomised, placebo-controlled trial.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Calculi; Double-Blind Method; Female; Humans; Indome

2022
Rectal indometacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): a single-centre, double-blind, randomised, placebo-controlled trial.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Calculi; Double-Blind Method; Female; Humans; Indome

2022